Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Relapse Multiple Myeloma · Refractory Multiple Myeloma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Wisconsin, Madison, Wisconsin, United States
Study leads
Natalie Callander, MD
Principal Investigator
University of Wisconsin, Madison